10x Genomics Reports Q1 2026 Earnings and Financial Performance
10x Genomics (TXG) reported first-quarter earnings for fiscal year 2026, showing mixed performance across revenue segments. Consumables revenue increased by 13%, driven by growth in single-cell and spatial products, while instrument sales declined significantly due to reduced demand for Chromium and spatial instruments.
Tickers: $TXG
Topics: cash_position consumables gross_margin instruments operating_expenses revenue